Actively Recruiting
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers
Led by Daewoong Pharmaceutical Co. LTD. · Updated on 2024-12-18
76
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The safety and tolerability of single and multiple administration of DWP212525
CONDITIONS
Official Title
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adult male volunteers aged 19 to 55 years, Caucasian
- Body weight between 50.0 kg and 90.0 kg
- Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2
- Provided informed consent and received sufficient explanation about the study
- Eligible for participation as determined by the study criteria
You will not qualify if you...
- History of clinically significant hepatobiliary diseases
- Clinically significant acute or chronic infections or related past history
- Hemato-oncologic diseases, including malignant tumors
- Past history or confirmed tuberculosis infection based on IGRA test and chest X-ray
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here